RNN Rexahn Pharmaceuticals Inc.

1.98
-0.03  -1%
Previous Close 2.01
Open 2.01
Price To book 3.54
Market Cap 56350414
Shares 28,459,805
Volume 432,604
Short Ratio 4.84
Av. Daily Volume 373,672

SEC filingsSee all SEC filings

  1. 8-K - Current report 171141047
  2. 424B5 - Prospectus [Rule 424(b)(5)] 171140078
  3. 8-K - Current report 171135759
  4. 8-K - Current report 171065056
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171008818

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2Q 2018.
RX-3117 in combination with Abraxane
First-line pancreatic cancer
Phase 2a initial presented at ASCO June 4, 2017. Further data released at ESMO 2017.
RX-3117
Advanced bladder cancer
Phase 2a initial data due 4Q 2017.
Supinoxin
Triple negative breast cancer
Updated Phase 2a data presented at ASCO GI January 20, 2017. Further data due 4Q 2017.
RX-3117
Relapsed and refractory pancreatic cancer
Phase 2a second stage enrollment commenced February 2016. Initial data due 4Q 2017.
Archexin
Renal cell carcinoma (RCC) - cancer

Latest News

  1. Rexahn Announces $8 Million Registered Direct Offering
  2. Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher
  3. Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117
  4. Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC
  5. Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress
  6. Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology (ESMO) Congress
  7. Rexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference
  8. Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology (ESMO) Congress
  9. Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors
  10. Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™
  11. Today's Research Reports on Trending Tickers: Rexahn Pharmaceuticals and Valeant Pharmaceuticals
  12. Rexahn, Pipeline Updates, Q2 Financial Review, Analysts Target Price
  13. Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
  14. Rexahn posts 2Q profit
  15. Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results
  16. Rodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update
  17. Today's Research Reports on Stocks to Watch: Rexahn Pharmaceuticals and Depomed

SEC Filings

  1. 8-K - Current report 171141047
  2. 424B5 - Prospectus [Rule 424(b)(5)] 171140078
  3. 8-K - Current report 171135759
  4. 8-K - Current report 171065056
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171008818
  6. EFFECT - Notice of Effectiveness 17960890
  7. CORRESP [Cover] - Correspondence
  8. S-3/A [Amend] - Registration statement under Securities Act of 1933 17952437
  9. S-3/A [Amend] - Registration statement under Securities Act of 1933 17927873
  10. 8-K - Current report 17906938